Results 241 to 250 of about 133,417 (336)

Tolerability, toxicity, and outcomes following surgical and non-surgical approaches to the management of patients with locally advanced oesophageal squamous cell carcinoma: multicentre retrospective cohort study. [PDF]

BJS Open
RadioRoux Collaborative .
europepmc   +1 more source

The role and implication of platelet‐rich plasma in male factor infertility: A systematic review of human studies

Andrology, EarlyView.
Abstract Background Cryopreservation causes sperm injury and the success of surgical sperm retrieval (SSR) for azoospermic men is just over half depending on the cause of azoospermia. The role of autologous platelet‐rich plasma (PRP) in male factor infertility (MFI) is unclear. Objective To conduct a systematic review of the role of PRP in MFI focusing
Karl H. Pang
wiley   +1 more source

Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomised controlled trial (PALACE-3). [PDF]

BMJ Open
Wang X, Li C, Cao Y, Kang X, Leng X, Zheng Y, Zheng B, Guo W, Jing H, Han Y, Chen C, Li Y, Li H.   +12 more
europepmc   +1 more source

Long‐term quality of life in patients with bladder cancer following radical cystectomy

BJU International, Volume 135, Issue 4, Page 675-683, April 2025.
Objectives To investigate changes in quality of life (QoL) up to 8 years after radical cystectomy (RC) and compare QoL after RC with a gender‐ and age‐matched Dutch normative population. Furthermore, we aimed to identify patient characteristics associated with QoL and QoL trajectories after RC.
Emine Akdemir, Martijn M. Stuiver, Maaike W. van de Kamp, Jolanda Bloos ‐ van der Hulst, Laura S. Mertens, Kees Hendricksen, Wim H. van Harten, Anne M. May, Maike G. Sweegers   +8 more
wiley   +1 more source

Beyond the SANO Trial: Reshaping Organ Preservation for Esophageal Cancer in the Era of Potent Neoadjuvant Therapies. [PDF]

Thorac Cancer
Wang J, Hui Z, Pang Q.
europepmc   +1 more source

Head and Neck Cancer Immunotherapy: Overcoming Limitations and Enhancing Efficacy

Cancer Science, EarlyView.
ICI‐included therapies are standard for R/M HNSCC patients. In particular, neoadjuvant ICI therapy shows promising clinical results even in nontreated resectable HNSCC patients. In addition, cancer vaccine, immune cell‐based therapy, immunomodulation therapy, and TME targeting therapy may combine with ICI.
Hirofumi Shibata, Masashi Kuroki, Ryo Kawaura, Tatsuhiko Yamada, Ryota Iinuma, Hiromasa Ishihara, Hiroshi Okuda, Kenichi Mori, Takenori Ogawa   +8 more
wiley   +1 more source

Highly Active Antiretroviral Therapy (HAART) - "Sulfonyl", and anal cancer outcomes from patients living with HIV: a retrospective cohort. [PDF]

Infect Agent Cancer
Miranda RR, Rocha EA, de Almeida Robatto AA, Galhera DA, Victor CR, Imbrahim KY, Moniz CMV.   +6 more
europepmc   +1 more source

Impact of TP53, KRAS, and APC Mutations on Neoadjuvant Chemotherapy Outcomes in Locally Advanced Rectal Cancer

Cancer Science, EarlyView.
Genetic profiling of TP53, KRAS, and APC mutations reveals potential as predictors of neoadjuvant chemotherapy efficacy in locally advanced rectal cancer, aiding personalized treatment strategies to improve survival and reduce recurrence risks. ABSTRACT Despite recent advances in neoadjuvant strategies for locally advanced rectal cancer (LARC), optimal
Tomohiro Takeda, Tatsuya Shonaka, Mishie Tanino, Katsuro Enomoto, Shoichiro Mizukami, Masahide Otani, Mizuho Ohara, Chikayoshi Tani, Kimiharu Hasegawa, Takahiro Ishii, Ayumu Sugitani, Chiho Maeda, Yusuke Ono, Yuji Uno, Nobue Tamamura, Shin‐ichi Chiba, Yusuke Mizukami, Hideki Yokoo   +17 more
wiley   +1 more source

Sarcopenia following concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. [PDF]

J Gastrointest Oncol
Vongcharoenpol T, Chaochankit W, Ruangsin S, Laohawiriyakamol S, Leelakiatpaiboon S, Ina N, Kittichet R, Sunpaweravong P, Sunpaweravong S.   +8 more
europepmc   +1 more source

Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited‐Stage Small‐Cell Lung Cancer in the Phase 3 ADRIATIC Trial

Cancer Science, EarlyView.
This Japan subgroup analysis of the global phase 3 ADRIATIC trial showed that consolidation durvalumab versus placebo improves outcomes, and is well tolerated, in patients with limited‐stage small‐cell lung cancer following concurrent chemoradiotherapy comprising cisplatin or carboplatin‐based chemotherapy and once‐daily or twice‐daily radiotherapy ...
Yoshitaka Zenke, Yoshimasa Shiraishi, Yasushi Goto, Koichi Azuma, Kyoichi Okishio, Hirokazu Ogino, Yoshitsugu Horio, Satoshi Oizumi, Manabu Hayama, Masahiro Nii, Masaya Harada, Helen Mann, Yuka S. Olivo, Haiyi Jiang, Suresh Senan   +14 more
wiley   +1 more source